Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases.

Shengule S, Alai S, Bhandare S, Patil S, Gautam M, Mangaonkar B, Gupta S, Shaligram U, Gairola S

Open source

DOI
10.3390/vaccines12040433
Published
2024 Apr 18
Container
Vaccines
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/vaccines12040433,
  title = {Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases.},
  author = {Shengule S and Alai S and Bhandare S and Patil S and Gautam M and Mangaonkar B and Gupta S and Shaligram U and Gairola S},
  year = {2024},
  journal = {Vaccines},
  doi = {10.3390/vaccines12040433},
  url = {https://doi.org/10.3390/vaccines12040433}
}

RIS

TY  - JOUR
TI  - Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases.
AU  - Shengule S
AU  - Alai S
AU  - Bhandare S
AU  - Patil S
AU  - Gautam M
AU  - Mangaonkar B
AU  - Gupta S
AU  - Shaligram U
AU  - Gairola S
PY  - 2024
JO  - Vaccines
DO  - 10.3390/vaccines12040433
UR  - https://doi.org/10.3390/vaccines12040433
ER  - 

APA

S, S., S, A., S, B., S, P., M, G., B, M., S, G., U, S., & S, G. (2024). Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases.. Vaccines. https://doi.org/10.3390/vaccines12040433

Source records